N. Ubags (Epalinges, Switzerland), D. Bogaert (Edinburgh, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells
R. Sana (South San Francisco, United States of America), E. Gordon (South San Francisco, United States of America), A. Navratil (South San Francisco, United States of America), E. Sandvik (South San Francisco, United States of America), J. Woo (South San Francisco, United States of America), R. Saggar (South San Francisco, United States of America), E. Moran (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America)
|    |
SARS-CoV-2 D614G-infected airway organoids reveal enhanced viral fitness in COPD bronchi
L. Chan (Singapore, Singapore), D. Anderson (Singapore, Singapore), A. Kang (Singapore, Singapore), R. Foo (Singapore, Singapore), A. Gamage (Singapore, Singapore), P. Tiew (Singapore, Singapore), M. Koh (Singapore, Singapore), K. Lee (Singapore, Singapore), K. Nichol (Newcastle, NSW, Australia), P. Pathinayake (Newcastle, NSW, Australia), T. Yeo (Singapore, Singapore), B. Oliver (Sydney, NSW, Australia), P. Wark (Newcastle, NSW, Australia), L. Wang (Singapore, Singapore), S. Chotirmall (Singapore, Singapore)
| |
A novel short isoform of ACE2 is expressed in ciliated airway epithelium and is induced by interferon and rhinovirus infection but not SARS-COV-2; implications for COVID-19 interferon treatment
C. Jackson (Southampton, United Kingdom), C. Blume (Southampton, United Kingdom), C. Spalluto (Southampton, United Kingdom), C. Mc Cormick (Southampton, United Kingdom), D. Davies (Southampton, United Kingdom), J. Lucas (Southampton, United Kingdom), V. Mennella (Southampton, United Kingdom), G. Wheway (Southampton, United Kingdom)
| |
The mucosal immunity of the respiratory tract in COVID-19 convalescent healthcare professionals
N. Kryukova (Moscow, Russian Federation), N. Abramova (Moscow, Russian Federation), E. Khromova (Moscow, Russian Federation), V. Zakharova (Moscow, Russian Federation), S. Skhodova (Moscow, Russian Federation), I. Bisheva (Moscow, Russian Federation), A. Vinnitskaya (Moscow, Russian Federation), M. Kostinov (Moscow, Russian Federation), I. Baranova (Moscow, Russian Federation), O. Svitich (Moscow, Russian Federation), A. Chuchalin (Moscow, Russian Federation)
| |
Sex-Hormone Specific Responses to SARS-CoV2 in an iPSC-derived human model of Type 2 Alveolar Epithelial Cells
I. Oglesby (Dublin, Ireland), A. Glasgow (Dublin, Ireland), M. Ozaki (Dublin, Ireland), C. Greene (Dublin, Ireland), K. Hurley (Dublin, Ireland)
| |
Single-cell RNA sequencing of blood antigen-presenting cells in severe Covid-19 reveals multi-process defects in antiviral immunity
M. Saichi (Paris, France), M. Ladjemi (Paris, France), S. Korniotis (Paris, France), C. Rousseau (Paris, France), Z. Ait-Hamou (Paris, France), L. Massenet (Paris, France), E. Amblard (Paris, France), F. Noel (Paris, France), Y. Marie (Paris, France), D. Bouteiller (Paris, France), J. Medvedovic (Paris, France), F. Pène (Paris, France), V. Soumelis (Paris, France)
| |
Modulation of the innate and adaptive immune system during coronavirus infection.
P. Hohensinner (Vienna, Austria), M. Salzmann (Vienna, Austria), J. Wojta (Vienna, Austria), R. Plasenzotti (Vienna, Austria)
| |
LSC - 2021 - Use of differentiated primary human airway epithelial models to study SARS-CoV-2 infection biology and pathogenesis
W. Ying, M. Thaler (M.Thaler@lumc.nl / Leiden University Medical Center,Leiden), D. K. Ninaber (D.K.Ninaber@lumc.nl / Leiden University Medical Center,Leiden), A. M. Van Der Does (A.van_der_Does@lumc.nl / Leiden University Medical Center,Leiden), N. S. Ogando (N.S.Lima_Leite_Ogando@lumc.nl / Leiden University Medical Center,Leiden), H. Beckert (hendrik.beckert@rlk.uk-essen.de / University Medical Center Essen – Ruhrlandklinik,Essen), C. Taube (christian.taube@rlk.uk-essen.de / University Medical Center Essen – Ruhrlandklinik,Essen), C. Salgado Benvindo Da Silva (C.Salgado_Benvindo_da_Silva@lumc.nl / Leiden University Medical Center,Leiden), P. J. Bredenbeek (p.j.bredenbeek@lumc.nl / Leiden University Medical Center,Leiden), P. S. Hiemstra (P.S.Hiemstra@lumc.nl / Leiden University Medical Center,Leiden), M. J. Van Hemert (M.J.van_Hemert@lumc.nl / Leiden University Medical Center,Leiden)
| |
Alveolar type II cells harbouring SARS-CoV-2 show senescence with a proinflammatory phenotype
K. Paschalaki (London, United Kingdom), K. Evangelou (Athens, Greece), D. Veroutis (Athens, Greece), P. Foukas (Athens, Greece), C. Kittas (Athens, Greece), A. Tzioufas (Athens, Greece), L. De Leval (Lausanne, Switzerland), D. Vassilakos (Athens, Greece), P. Barnes (London, United Kingdom), V. Gorgoulis (Athens, Greece)
| |
Discussion
| |